KAISHA Introduces Pathbreaking Innovation with the launch of ‘KAISHA LIFESCIENCES”

2026-07-26 07:27:16 Business

762

Mumbai, India ? September 24, 2018: The three-decade old partnership of Kairus Dadachanji and Shapoorji Pallonji Mistry has resulted in yet another milestone in India?s pharmaceutical landscape with the birth of ?KAISHA LIFESCIENCES?.

With multi-crore investment and a team of skilled pharma specialists committed to develop superior quality generic injectables and any other forms of medicine, KAISHA LIFESCIENCES is a privately-owned company, established in Mumbai, with the sole purpose of developing top quality medication.

?After the phenomenal success of SOVEREIGN Pharma, SHAKAI Packaging and SCHOTT KAISHA, we are extremely proud to introduce this new venture. We aim to create a brand that can not only be relied on, but trusted by consumers all over the world?, says Rishad Dadachanji, Managing Director, KAISHA LIFESCIENCES. ?Our philosophy of ?One Quality for All? enables us to maintain the highest standards for all our products that are developed and manufactured under stringent protocols of quality control, to ensure ?PATIENT SAFETY?.

In addition to the most advanced products offered by KAISHA LIFESCIENCES, the new set-up will offer a portfolio of contract research services from its R&D site, located in Daman, India which is equipped with a large variety of sophisticated equipment enabling customers to develop a wide and complex range of products. Started with an initial investment of INR 20 crores, the modern site is spread across 3 stories with dedicated formulation development and analytical development labs.

?Our aim is to support the ?Vision 2030? for the Indian Life Sciences Industry of becoming the largest and most reliable drug supplier in the world whilst providing affordable and high quality drugs to fellow Indians. We are here to service the needs of the pharmaceutical industry for several decades to come, ensuring continued stability and reliability for our partners and the end consumers?, says Rishad Dadachanji. Under this vision, the industry is expected to sustain its growth trajectory of 11 to 12 percent per annum and grow 7 to 8 times, to a size of USD 190 to 200 billion (`INR 13.75 to 14.45 trillion) by the year 2030.

KAISHA LIFESCIENCES boasts of ingenuous platform technologies and speciality in complex capabilities such as:

Emulsions & Nanoemulsions
Liposomes (Pegylated & Non-pegylated)
Lipid complexes
Depot Injections (Microspheres & Implants)
Nanoparticles
Micellar systems
Topical gels
Ophthalmic emulsions
Starting today, KAISHA LIFESCIENCES also introduces its new website design and content enhancements that will help customers researchers to easily navigate and access product and technical information.